drugset / Trial / NCT02691598

Dexmedetomidine Hydrochloride in the Prevention of Organ Failure Following Severe Acute Pancreatitis

NCT02691598 ↗

Phase 4 Unknown 314 enrolled Nanjing University School of Medicine
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Cytokines such as such as TNF-a, IL-1, IL-6 correlate with the severity of pancreatitis.Neuroendocrine pathways, such as the sympathetic nervous system or parasympathetic nervous system, in turn, have some impact on the immune systems, through a-2 adrenoreceptor stimulation or the cholinergic anti-inflammatory pathway. The investigators aim to use Dexmedetomidine Hydrochloride to decrease the activity of sympathetic nervous system, thus relieve inflammation response.

Timeline

Start
2016-02
Primary completion
2016-02
Completion
2017-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 4 ug/ml Other